2018 Annual Meeting

March 19, 2018: 12:00 PM - 1:00 PM

Lunch is included with course registration fee.

TNM in 2018: Problems in Daily Practice

Moderator

Wendy Frankel, M.D., The Ohio State University-Wexner Medical Center, Columbus, OH

Panelists
  • N. Volkan Adsay, M.D., Medical College of Wisconsin, Milwaukee, WI
  • Laura Tang, M.D., Ph.D., Memorial-Sloan-Kettering Cancer Center, Los Angeles, CA
  • Sanjay Kakar, M.D., University of California, San Francisco, San Francisco, CA
Description

The American Joint Committee on Cancer TNM 8th edition will be effective on January 1, 2018. Join your colleagues to learn about significant changes and new questions. Correct staging is vital to help with prognosis and treatment decisions to provide the best patient care and cancer data collection.

Target Audience

Pathologists, residents and fellows

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Understand updated criteria for staging gastrointestinal malignancies
  • Recognize changes in staging pancreatic malignancies
  • Know the appropriate synoptic reports to use for staging GI neuroendocrine tumors

March 20, 2018: 12:00 PM - 1:00 PM

Hot Topics in Lung Pathology: From the Morphologic to the Molecular

Moderator

Carol F. Farver, M.D., Cleveland Clinic Foundation, Cleveland, OH

Panelists
  • Andrew Churg, M.D., Ph.D., University of British Columbia, Vancouver, BC, Canada
  • Sanja Dacic, M.D., Ph.D., University of Pittsburgh, Pittsburgh, PA
  • Jeffrey Myers, M.D., The University of Michigan, Ann Arbor, MI
  • Lynette Marie Sholl, M.D., Brigham and Women's Hospital, Boston, MA
Description

The morphologic criteria and the appropriate molecular testing for both neoplastic and non-neoplastic lung diseases are undergoing rapid changes. Neoplasms of the lung require more specific molecular studies to define appropriate therapies and non-neoplastic lung pathology requires more precise criteria as new therapies for these diseases emerge. Attend this session to get updated criteria for pathologic definitions for the common interstitial lung diseases and current recommendations for molecular testing. This session will also review the classification for lung tumors using the American Joint Committee on Cancer TNM 8th edition.

Target Audience

Pathologists, residents and fellows

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Understand updated criteria for the pathologic definitions for the common interstitial lung diseases
  • Know the current recommendations for the appropriate molecular testing for lung carcinomas.
  • Recognize the new changes in staging of lung malignancies in the 8th edition of the TNM classification for lung tumors

March 21, 2018: 12:00 PM - 1:00 PM

Continuing Certification: Update on the American Board of Pathology's MOC Program

Moderator

Rebecca Johnson, M.D., American Board of Pathology, Tampa, FL

Panelists
  • Ritu Nayar, M.D., Northwestern University, Chicago, IL
  • Michael Jones, M.D., Maine Medical Center, Portland, ME
  • Eric Glassy, M.D., Affiliated Pathologists Medical Group, Torrance, CA
Description

Join Rebecca Johnson, M.D., CEO of the American Board of Pathology (ABP), and ABP Diplomates to discuss the recent and anticipated changes to the Maintenance of Certification (MOC) program.

Target Audience

Diplomates of the ABP, residents and fellows, pathologists interested in continuing certification.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Know recent changes to the ABP’s MOC Program, including exam modules, remote exam administration
  • Understand the value of longitudinal assessment and the design of the ABPath CertLink pilot
  • Recognize future enhancements to the MOC program, including ACCME Program and Activity Reporting System (PARS)

March 22, 2018: 12:00 PM - 1:00 PM

Head and Neck Pathology - New and Improved

Moderator

James Lewis Jr., M.D., Vanderbilt University Medical Center, Nashville, TN

Panelists
  • Justin Bishop, M.D., University of Texas, Southwestern Medical Center, Dallas, TX
  • Nora Katabi, M.D., Memorial Sloan Kettering, New York, NY
  • Margaret Brandwein-Weber, M.D., Mt. Sinai Hospital, New York, NY
Description

Much has changed in head and neck pathology in the past year, with the new WHO Classification of tumors, new immunohistochemical and molecular markers for older and recently described tumors, and the American Joint Committee on Cancer TNM 8th edition staging of head and neck cancers. Your colleagues will discuss how to utilize new immunohistochemical stains and molecular test to differentiate salivary gland and sinonasal tumors.

Target Audience

Practicing pathologists, residents, and fellows.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Properly utilize new immunohistochemical stains and molecular tests to differentiate and classify salivary gland tumors
  • Properly utilize new immunohistochemical stains and molecular tests to differentiated and classify sinonasal tumors

 

Continuing Medical Education

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Register Now!

Meetings

view more